The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of Medicare Advantage (MA) on timely hormonal intensification in metastatic hormone sensitive prostate cancer.
 
Baqir Jafry
No Relationships to Disclose
 
Chuan Lu
No Relationships to Disclose
 
Jonathan Ji
No Relationships to Disclose
 
Raj Bhanvadia
No Relationships to Disclose
 
Qian Qin
Honoraria - MashupMedia; MJH Life Sciences
Consulting or Advisory Role - Exelixis
 
Joseph Vento
Employment - HCA Healthcare (I)
 
Kevin Courtney
Consulting or Advisory Role - Novartis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Celgene/Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); DualityBio (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Janssen Research & Development (Inst); Lilly (Inst); Myovant Sciences (Inst); Novartis (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Surface Oncology (Inst)
Patents, Royalties, Other Intellectual Property - My spouse receives patent royalties from Athena Diagnostics, Inc. (I)
 
Jue Wang
No Relationships to Disclose
 
Waddah Arafat
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); Merck (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
 
Daniel Yang
No Relationships to Disclose
 
Suzanne Cole
Research Funding - Exelixis (Inst); Merck (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Clovis Oncology; Dendreon; Foundation Medicine; Gilead Sciences; Janssen Scientific Affairs; Myovant Sciences; Procept Biorobotics; Progenics; Seagen
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Aptitude Health; Clinical Care Options; Curio Science; Mashup Media; MJH Life Sciences; Peerview
Consulting or Advisory Role - Aravive; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Gilead Sciences; Janssen; Lilly; Loxo/Lilly; Merck; Novartis; Pfizer; Sanofi/Aventis; Seagen; Xencor
Research Funding - ALX Oncology (Inst); Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Janux Therapeutics (Inst); Loxo/Lilly (Inst); OncoC4; Pfizer (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Bayer
Other Relationship - ASCO; Kidney Cancer Association; KidneyCan; Myrovlytis Trust; Winn Foundation
 
Changchuan Jiang
Honoraria - MJH Life Sciences